Vanda Pharmaceuticals Inc. (VNDA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 80M 160M 240M Q3 '24: 190.9M Q4 '24: 198.8M Q1 '25: 201.4M Q2 '25: 203.5M Q3 '25: 212.1M Q4 '25: 216.1M Q1 '26: 217.8M Q2 '26: 215.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

0 80M 160M 240M Q1 '19: 174.6M Q2 '19: 185.2M Q3 '19: 193.9M Q4 '19: 201.2M Q1 '20: 211.4M Q2 '20: 215.1M Q3 '20: 216.8M Q4 '20: 223.3M Q1 '19 Q2 '19 Q3 '19 Q4 '19 Q1 '20 Q2 '20 Q3 '20 Q4 '20

Operating Income TTM

-210M -140M -70M 0 70M 140M 210M Q3 '24: -37.5M Q4 '24: -40.7M Q1 '25: -72.5M Q2 '25: -100.8M Q3 '25: -121.1M Q4 '25: -151.2M Q1 '26: -160.4M Q2 '26: -185.7M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '23: 11.8M Q4 '24: -18.9M Q1 '25: -44.2M Q2 '25: -66.9M Q3 '25: -84.2M Q4 '25: -220.5M Q1 '26: -239.5M Q2 '26: -274.9M Q3 '23 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 5M 10M 15M Q3 '24: 12.2M Q4 '24: 11.3M Q1 '25: 11.4M Q2 '25: 11.4M Q3 '25: 11.8M Q4 '25: 13M Q1 '26: 12.7M Q2 '26: 13.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '24: -17.7M Q4 '24: -15.8M Q1 '25: -56.5M Q2 '25: -64.8M Q3 '25: -81.8M Q4 '25: -109.4M Q1 '26: -126.5M Q2 '26: -142.3M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q3 '24: -18.2M Q4 '24: -16.2M Q1 '25: -57.4M Q2 '25: -65.9M Q3 '25: -83M Q4 '25: -110.4M Q1 '26: -127.3M Q2 '26: -143M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '24: 57.8M Q2 '24: 58.2M Q3 '24: 58.3M Q1 '25: 58.5M Q2 '25: 59M Q3 '25: 59.1M Q1 '26: 59.5M Q2 '26: 60.2M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '24: -0.29 Q4 '24: -0.33 Q1 '25: -0.76 Q2 '25: -1.14 Q3 '25: -1.43 Q4 '25: -3.73 Q1 '26: -4.05 Q2 '26: -4.63 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.